{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Akebia Therapeutics, Inc.
Akebia Therapeutics Hits Day Low of $2.08 Amid Price Pressure
Akebia Therapeutics, Inc. has faced significant stock volatility, dropping sharply today and over the past week. Despite recent challenges, the company reported strong quarterly net sales and has outperformed the S&P 500 over the past year and three years, indicating resilience in a competitive market.
Akebia Therapeutics Achieves Multibagger Status with 123.31% Stock Increase Over Past Year
Akebia Therapeutics, Inc. has recently undergone a revision in its stock evaluation, reflecting its strong performance metrics. The company has achieved impressive returns over various timeframes, significantly outpacing the S&P 500. Despite facing challenges, Akebia's recent positive results and reduced costs indicate a promising outlook for investors.
Is Akebia Therapeutics, Inc. technically bullish or bearish?
As of August 7, 2025, Akebia Therapeutics, Inc. has a mildly bullish trend, supported by daily moving averages, but caution is advised due to mildly bearish weekly MACD and KST indicators, despite outperforming the S&P 500 over the past year.
Is Akebia Therapeutics, Inc. overvalued or undervalued?
As of March 6, 2017, Akebia Therapeutics, Inc. is considered overvalued and risky due to its high Price to Book Value of 42.42, negative EV to EBIT of -51.46, and troubling ROE of -184.16%, despite a strong year-to-date return of 55.79%.
Is Akebia Therapeutics, Inc. overvalued or undervalued?
As of March 6, 2017, Akebia Therapeutics, Inc. is considered "risky" and overvalued with concerning financial metrics, including a Price to Book Value of 42.42 and a negative P/E ratio of -20.31, indicating significant financial distress compared to its peers.
Is Akebia Therapeutics, Inc. technically bullish or bearish?
As of May 7, 2025, Akebia Therapeutics, Inc. has shifted to a bullish trend, supported by strong indicators like a bullish MACD, moving averages, and KST across multiple time frames, despite the RSI showing no signal.
Who are in the management team of Akebia Therapeutics, Inc.?
As of March 2022, the management team of Akebia Therapeutics, Inc. includes Independent Chairman Mr. Adrian Adams and President/CEO Mr. John Butler, along with several Independent Directors: Mr. Mark Enyedy, Dr. Steven Gilman, Dr. Maxine Gowen, Mr. Michael Heffernan, and Mr. Michael Rogers. They guide the company's strategic direction and operations.
What does Akebia Therapeutics, Inc. do?
Akebia Therapeutics, Inc. is a biopharmaceutical company specializing in therapeutics based on hypoxia-inducible factor (HIF) biology, with recent net sales of $57 million and a market cap of $919.23 million. The company is currently loss-making, with a P/E ratio of NA and a dividend yield of 0%.
How big is Akebia Therapeutics, Inc.?
As of Jun 18, Akebia Therapeutics, Inc. has a market capitalization of 919.23 million and reported net sales of 184.92 million with a net profit loss of 45.31 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
